Top Banner Top Banner

Clinical Trials
Ongoing Clinical Trials
Recruiting
A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer
Conditions: Kidney Neoplasms
Interventions: Drug: Sunitinib malate, Other: Placebo
Phase: Phase III
Recruiting
Sorafenib in Treating Patients at Risk of Relapse After Undergoing Surgery to Remove Kidney Cancer
Conditions: Kidney Cancer
Interventions: Drug: sorafenib tosylate, Procedure: adjuvant therapy
Phase: Phase III
Recruiting
Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer
Conditions: Kidney Neoplasms
Interventions: Drug: Axitinib (AG-013736), Drug: Sorafenib
Phase: Phase III
Recruiting
Clinical Trial to Assess the Importance of Nephrectomy
Conditions: Metastatic Renal Cell Carcinoma
Interventions: Procedure: Nephrectomy, Other: Sunitinib alone
Phase: Phase III
Recruiting
Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer
Conditions: Kidney Cancer
Interventions: Drug: sunitinib malate, Genetic: gene expression analysis, Other: biologic sample preservation procedure, Other: laboratory biomarker analysis, Procedure: therapeutic conventional surgery
Phase: Phase III
Recruiting
Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy
Conditions: Kidney Cancer
Interventions: Biological: bevacizumab, Drug: everolimus, Other: placebo
Phase: Phase III
Recruiting
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
Conditions: Metastatic Renal Cell Carcinoma
Interventions: Drug: Dovitinib, Drug: Sorafenib
Phase: Phase III
Recruiting
A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)
Conditions: Renal Cell Carcinoma, Cancer
Interventions: Drug: pazopanib, Drug: placebo
Phase: Phase III
Recruiting
Comparison of Sequential Therapies With Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma
Conditions: Metastatic Renal Cell Carcinoma
Interventions: Drug: Sorafenib-sunitinib, Drug: Sunitinib-sorafenib
Phase: Phase III
Recruiting
Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery
Conditions: Kidney Cancer
Interventions: Drug: everolimus, Other: placebo
Phase: Phase III
Recruiting
VEGF Trap in Treating Patients With Metastatic or Unresectable Kidney Cancer
Conditions: Kidney Cancer
Interventions: Biological: aflibercept
Phase: Phase II
Recruiting
A Study of Neoadjuvant Sutent for Patients With Renal Cell Carcinoma
Conditions: Renal Cell Carcinoma
Interventions: Drug: Sunitinib Malate (Sutent)
Phase: Phase II
Recruiting
Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Sarcomatoid Renal Cell Carcinoma
Conditions: Renal Cell Carcinoma, Kidney Cancer
Interventions: Drug: Capecitabine, Drug: Gemcitabine, Drug: Bevacizumab
Phase: Phase II
Recruiting
Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer
Conditions: Kidney Cancer
Interventions: Drug: sunitinib malate
Phase: Phase II
Recruiting
Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma
Conditions: Renal Cell Carcinoma, Neoplasm Metastases
Interventions: Drug: Gemcitabine, Drug: Sunitinib
Phase: Phase II
Recruiting
Phase II Study of Vandetanib in Individuals With Kidney Cancer
Conditions: Renal Cancer, Von Hippel Lindau
Interventions: Drug: ZACTIMA (Vandetanib) (ZD6474)
Phase: Phase II
Recruiting
Study of Sunitinib Administered as 4/2 vs. 2/1 Schedule in Advanced Renal Cell Carcinoma (RCC)
Conditions: Metastatic Renal Cell Carcinoma
Interventions: Drug: Sunitinib 2/1, Drug: Sunitinib 4/2
Phase: Phase II
Recruiting
Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RADOO1
Conditions: Kidney Neoplasms, Kidney (Renal Cell) Cancer
Interventions: Drug: RAD001, Drug: bevacizumab, Procedure: CT Scan
Phase: Phase II
Recruiting
RAPTOR: RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Tumors Program in Europe
Conditions: Carcinoma, Renal Cell, Non Clear Cell Renal Carcinoma, Papillary Cell Renal Carcinoma, Adenocarcinoma
Interventions: Drug: Everolimus
Phase: Phase II
Recruiting
Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma
Conditions: Renal Cell Carcinoma, Kidney Cancer
Interventions: Drug: avastin, Drug: temsirolimus
Phase: Phase II
Recruiting
Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma
Conditions: Renal Cell Carcinoma, Renal Cancer
Interventions: Drug: Everolimus
Phase: Phase II
Recruiting
RAD001 for Non-clear Cell Renal Cell Carcinoma (RCC)
Conditions: Renal Cell Carcinoma
Interventions: Drug: RAD001
Phase: Phase II
Recruiting
Everolimus(RAD001) For Advanced Renal Cell Carcinoma(RCC)Before Kidney Removal
Conditions: Kidney Cancer
Interventions: Drug: everolimus
Phase: Phase II
Recruiting
Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer
Conditions: Carcinoma, Renal Cell
Interventions: Drug: axitinib, Drug: axitinib, Drug: axitinib
Phase: Phase II
Recruiting
Sunitinib and Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer
Conditions: Kidney Cancer
Interventions: Biological: therapeutic allogeneic lymphocytes, Drug: sunitinib malate
Phase: Phase II
Recruiting
Bevacizumab, Autologous Tumor/DC Vaccine, IL-2 and IFNα-2b in Metastatic Renal Cell Carcinoma (RCC) Patients
Conditions: Metastatic Renal Cell Carcinoma
Interventions: Biological: DC vaccine, Drug: Bevacizumab, Biological: IL-2, Biological: IFN
Phase: Phase II
Recruiting
Bevacizumab Plus Ixabepilone to Treat Patients With Advanced Kidney Cancer
Conditions: Renal Cell Carcinoma
Interventions: Drug: Bevacizumab, Drug: Ixempra (Ixbepilone [BMS-247550]
Phase: Phase II
Recruiting
Neoadjuvant Sunitinib Treatment for Metastatic Clear Cell Renal Cell Carcinoma (RCC)
Conditions: Clear Cell Renal Cell Carcinoma, Metastasis
Interventions: Drug: Sunitinib
Phase: Phase II
Recruiting
Study of Sunitinib in Subjects With High Risk Renal Cell Carcinoma
Conditions: Renal Cell Carcinoma
Interventions: Drug: Sunitinib, Other: Tumor biopsy, Procedure: Nephrectomy, Other: Biomarkers
Phase: Phase II
Recruiting
Velcade and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma
Conditions: Metastatic Renal Cell Carcinoma
Interventions: Drug: velcade, sorabenib
Phase: Phase II
Recruiting
Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma
Conditions: Advanced Non-clear Cell Renal Cell Carcinoma
Interventions: Drug: Everolimus, Drug: Sunitinib
Phase: Phase II
Recruiting
A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer
Conditions: HLRCC, Metastatic Papillary RCC
Interventions: Drug: Bevacizumab, Drug: Erlotinib
Phase: Phase II
Recruiting
Pazopanib Hydrochloride in Treating Patients With Stage IV Kidney Cancer
Conditions: Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer
Interventions: Drug: pazopanib hydrochloride, Other: laboratory biomarker analysis, Other: immunologic technique
Phase: Phase II
Recruiting
Sunitinib Malate in Treating Patients With Previously Untreated Metastatic Kidney Cancer
Conditions: Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer
Interventions: Drug: sunitinib malate, Other: laboratory biomarker analysis, Genetic: reverse transcriptase-polymerase chain reaction, Genetic: polymorphism analysis
Phase: Phase II
Recruiting
Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer
Conditions: Clear Cell Renal Cell Carcinoma, Stage I Renal Cell Cancer, Stage II Renal Cell Cancer, Stage III Renal Cell Cancer
Interventions: Drug: pazopanib hydrochloride, Procedure: therapeutic conventional surgery
Phase: Phase II
Recruiting
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
Conditions: Kidney Cancer
Interventions: Drug: gemcitabine hydrochloride, Drug: sunitinib malate
Phase: Phase II
Recruiting
Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma
Conditions: Kidney Cancer
Interventions: Drug: Everolimus, Drug: Sunitinib
Phase: Phase II
Recruiting
A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma
Conditions: Renal Cell Carcinoma
Interventions: Drug: RAD001
Phase: Phase II
Recruiting
Resection of Pulmonary Metastasis in Clear Cell Renal Cell Carcinoma +/-Adjuvant Sunitinib Therapy (SMAT)
Conditions: Renal Cell Carcinoma, Pulmonary Metastases
Interventions: Drug: Sunitinib, Drug: Placebo
Phase: Phase II
Recruiting
Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy
Conditions: Kidney Cancer
Interventions: Drug: Pazopanib, Drug: Bevacizumab, Drug: Everolimus
Phase: Phase II
Recruiting
MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer
Conditions: Kidney Cancer
Interventions: Drug: Akt inhibitor MK2206, Drug: everolimus
Phase: Phase II
Recruiting
Temsirolimus-RCC-imaging
Conditions: Renal Cell Cancer
Interventions: Drug: Temsirolimus
Phase: Phase II
Recruiting
Brivanib Metastatic Renal Cell Carcinoma
Conditions: Male and Female Subjects 18 Years of Age and Older With Metastatic Renal Cell Carcinoma. Eligible Patients Must Have Undergone and Failed Prior Treatment.
Interventions: Drug: Brivanib alaninate, Genetic: Polymerase chain reaction, Other: Iodine I 124 chimeric monoclonal antibody G250, Procedure: Positron emission tomography/computed tomography, Genetic: Protein expression analysis, Other: Immunohistochemistry
Phase: Phase II
Recruiting
Neoadjuvant Axitinib in Locally Advanced Renal Cell Carcinoma (RCC)
Conditions: Kidney Cancer
Interventions: Drug: Axitinib
Phase: Phase II
Recruiting
Efficacy and Safety of Bevacizumab/Temsirolimus Combination to Treat Advanced Renal Cell Carcinoma
Conditions: Kidney Cancer
Interventions: Drug: Bevacizumab, Drug: Temsirolimus
Phase: Phase II
Recruiting
Study of Interleukin-2, Interferon-alpha and Bevacizumab in Metastatic Kidney Cancer
Conditions: Metastatic Renal Cell Carcinoma
Interventions: Drug: Interleukin-2, Drug: Interferon Alfa-2b, Drug: Bevacizumab
Phase: Phase II
Recruiting
Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma
Conditions: Carcinoma of Urinary Tract, Urethral Carcinoma, Carcinoma of Ureter, Carcinoma of Renal Pelvis
Interventions: Drug: Docetaxel, Biological: Ramucirumab DP, Biological: IMC-18F1
Phase: Phase II
Recruiting
A Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma
Conditions: Renal Cell Carcinoma
Interventions: Drug: Tivozanib
Phase: Phase II
Recruiting
Sorafenib in Elderly Patients With Metastatic Renal Cell Carcinoma
Conditions: Metastatic Renal Cell Carcinoma
Interventions: Drug: Sorafenib
Phase: Phase II
Recruiting
A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell Carcinoma
Conditions: Metastatic Clear Cell Renal Cell Carcinoma
Interventions: Drug: LY2510924, Drug: Sunitinib
Phase: Phase II
Recruiting
Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC)
Conditions: Renal Cell Carcinoma
Interventions: Drug: everolimus and bevacizumab
Phase: Phase II
Recruiting
Rotating Pazopanib and Everolimus to Avoid Resistance
Conditions: Clear Cell Renal Carcinoma
Interventions: Drug: Pazopanib, Drug: Everolimus, Drug: Pazopanib, Drug: Everolimus, Drug: Everolimus, Drug: Pazopanib
Phase: Phase II
Recruiting
PF-04856884 (CVX-060) In Combination With Axitinib In Patients With Previously Treated Metastatic Renal Cell Carcinoma
Conditions: Metastatic Renal Cell Carcinoma
Interventions: Biological: PF-04856884, Drug: AG-013736
Phase: Phase II
Recruiting
Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinoma
Conditions: Metastatic Renal Cell Carcinoma
Interventions: Drug: Everolimus
Phase: Phase II
Recruiting
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
Conditions: Head and Neck Cancer, Kidney Cancer, Liver Cancer, Sarcoma
Interventions: Drug: sorafenib tosylate, Genetic: gene expression analysis, Genetic: mutation analysis, Genetic: polymerase chain reaction, Other: enzyme-linked immunosorbent assay, Other: laboratory biomarker analysis, Other: pharmacological study
Phase: Phase II
Recruiting
Phase II Study of Alternating Sunitinib and Temsirolimus
Conditions: Metastatic Renal Cell Carcinoma
Interventions: Drug: Sunitinib, Drug: Temsirolimus
Phase: Phase II
Recruiting
Bevacizumab and Ixabepilone in Treating Patients With Advanced Kidney Cancer
Conditions: Kidney Cancer
Interventions: Biological: bevacizumab, Drug: ixabepilone, Genetic: gene expression analysis, Genetic: microarray analysis, Genetic: protein expression analysis, Genetic: proteomic profiling, Other: flow cytometry, Other: immunoenzyme technique, Other: immunohistochemistry staining method, Other: laboratory biomarker analysis, Procedure: dynamic contrast-enhanced magnetic resonance imaging
Phase: Phase II
Not yet recruiting
Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)
Conditions: Kidney Cancer
Interventions: Drug: Pazopanib, Drug: Temsirolimus, Behavioral: Quality of Life Assessment, Drug: Benadryl
Phase: Phase II
Not yet recruiting
Not yet recruiting
Evaluate the Efficacy of Sorafenib in Renal Cell Carcinoma Patients After a Radical Resection of the Metastases
Conditions: Metastatic Renal Cell Carcinoma
Interventions: Drug: sorafenib
Phase: Phase II
Not yet recruiting
Study of Efficacy and Safety of Sunitinib Given on an Individualized Schedule
Conditions: Clear Cell, Metastatic Renal Cell Carcinoma
Interventions: Drug: Sunitinib
Phase: Phase II


Clinical Trial Data provided by http://www.clinicaltrials.gov.




Last updated February 29, 2012